Home Stock

Stock Research: Jazz Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Jazz Pharmaceuticals

NasdaqGS:JAZZ IE00B4Q5ZN47
6
  • Value
    49
  • Growth
    15
  • Safety
    Safety
    14
  • Combined
    4
  • Sentiment
    49
  • 360° View
    360° View
    6
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Jazz Pharmaceuticals plc is a global biopharmaceutical company that develops medicines for serious diseases. It operates in the biopharmaceutical industry, with marketed medicines for sleep disorders, epilepsy, and cancer treatments, including Xywav, Epidiolex, and Rylaze. The company's product candidates include Zanidatamab, Vyxeos, and JZP815. In the last fiscal year, the company had a market cap of $6,803 million, profits of $3,623 million, and revenue of $4,069 million, with 2800 employees.

more
Strongest Rank Dividend Yield
Weakest Rank Analyst Opinions
Country Ireland
Industry Pharmaceuticals
Size Medium
Website jazzpharma.com
Index
Diversity Europe
NASDAQ
S&P MIDCAP
Jazz stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
49 53 47 62
Growth
15 63 85 55
Safety
Safety
14 32 20 40
Sentiment
49 82 64 36
360° View
360° View
6 73 59 38
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
89 80 72 77
Opinions Change
66 53 75 50
Pro Holdings
n/a 64 45 16
Market Pulse
40 57 33 33
Sentiment
49 82 64 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
49 53 47 62
Growth
15 63 85 55
Safety Safety
14 32 20 40
Combined
4 52 48 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
86 97 94 90
Price vs. Earnings (P/E)
41 48 52 56
Price vs. Book (P/B)
43 44 48 62
Dividend Yield
1 1 1 1
Value
49 53 47 62
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 70 50 78
Profit Growth
8 34 79 72
Capital Growth
18 93 92 24
Stock Returns
73 43 30 34
Growth
15 63 85 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
2 7 6 27
Refinancing
61 78 75 74
Liquidity
15 34 21 28
Safety Safety
14 32 20 40

Similar Stocks

Discover high‑ranked alternatives to Jazz Pharmaceuticals and broaden your portfolio horizons.

BMW

XTRA:BMW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Repsol

BME:REP
Country: Spain
Industry: Oil & Gas Integrated
Size: X-Large
Full Stock Analysis

Krka

LJSE:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Prosus

ENXTAM:PRX
Country: Netherlands
Industry: Internet Retail
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews